GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors

By sjmartinez • September 1, 2024

Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart Fail. 2024 Aug 16:S2213-1779(24)00561-4. doi: 10.1016/j.jchf.2024.07.006. Epub ahead of print. PMID: 39207323.

Tags: Cardiology/Epi, GLP-1 receptor agonists, Heart failure with preserved ejection fraction, Obesity, overweight, Publications, SGLT2is

Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes[...]

Genetic Variants Associated with the Biochemical Response to Vitamin D3 in the Multi-Ethnic Study of Atherosclerosis

Best CM, Li X, Rotter JI, Prince DK, Hsu S, Hoofnagle AN, Siscovick D, Taylor KD, Williams K, Michos ED, Psaty BM, Shea S, Rice[...]

Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum

Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum.[...]